Therapeutic Applications of Cell-Penetrating Peptides

Methods in Molecular Biology

Volumn 683, Issue , 2011, Pages 535-551

  Johnson, Randolph M ^a   Harrison, Stephen D ^a   Maclean, Derek ^a  

^a Toyota Technical Center USA Inc   (United States)

Author keywords

Cardioprotection; Cell penetrating peptides; Drug development; Drug discovery; Neuroprotection; Pain; PKC; Protein kinase C isozymes; TAT

Indexed keywords

CELL PENETRATING PEPTIDE; DRUG CARRIER;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PROTEIN TRANSPORT; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; CELL-PENETRATING PEPTIDES; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN TRANSPORT;

EID: 79952129002     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-919-2_38     Document Type: Chapter

References (68)

1. Daly, N.L., Rosengren, K.J., and Craik, D.J. (2009) Discovery, structure and biological activities of cyclotides. Adv. Drug Deliv. Rev. 61(11), 918–930.
2. Walensky, L.D., Kung, A.L., Escher, I., Malia, T.J., Barbuto, S., Wright, R.D.,Wagner, G., Verdine, G.L., and Korsmeyer, S.J. (2004) Activation of apoptosis in vivo by a hydrocar-bon-stapled BH3 helix. Science 305, 1466–1470.
3. Gump, J.M., and Dowdy, S.F. (2007) TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol. Med. 13, 443–448.
4. Chen, L., and Harrison, S.D. (2007) Cell-penetrating peptides in drug development: enabling intracellular targets. Biochem. Soc. Trans. 35, 821–825.
5. Prochiantz, A. (2008) Protein and peptide transduction, twenty years later a happy birthday. Adv. Drug Deliv. Rev. 60, 448–451.
6. Torchilin, V.P. (2008) Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 60, 548–558.
7. Wender, P.A., Galliher, W.C., Goun, E.A., Jones, L.R., and Pillow, T.H. (2008) The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug Deliv. Rev. 60, 452–472.
8. Frankel, A.D., Bredt, D.S., and Pabo, C.O. (1988) Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science 240, 70–73.
9. Joliot, A., Pernelle, C., Deagostini-Bazin, H., and Prochiantz, A. (1991) Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. U.S.A. 88, 1864–1868.
10. Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L.L., Pepinsky, B., and Barsoum, J. (1994) Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A. 91, 664–668.
11. Derossi, D., Joliot, A.H., Chassaing, G., and Prochiantz, A. (1994) The third helix of the antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 10444–10450.
12. Vives, E., Brodin, P., and Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010–16017.
13. Schwarze, S.R., Ho, A., Vocero-Akbani, A., and Dowdy, S.F. (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569–1572.
14. Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., and Sugiura, Y. (2001) Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276, 5836–5840.
15. Jones, S.W., Christison, R., Bundell, K., Voyce, C.J., Brockbank, S.M.V., Newham, P., and Lindsay, M.A. (2005) Characterisation of cell-penetrating peptide-mediated peptide delivery. Br. J. Pharmacol. 145, 1093–1102.
16. 7 . Chem. Biol. 8, 1123–1129.
17. Wender, P.A., Mitchell, D.J., Pattabiraman, K., Pelkey, E.T., Steinman, L., and Rothbard, J.B. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U.S.A. 97, 13003–13008.
18. Richard, J.P., Melikov, K., Brooks, H., Prevot, P., Lebleu, B., and Chernomordik, L.V. (2005) Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparin sulfate receptors. J. Biol. Chem. 280, 15300–15306.
19. Potocky, T.B., Menon, A.K., and Gellman, S.H. (2003) Cytoplasmic and nuclear delivery of a TAT-derived peptide and a b-peptide after endocytic uptake into HeLa cells. J. Biol. Chem. 278, 50188–50194.
20. Fittipaldi, A., Ferrari, A., Zoppe, M., Arcangeli, C., Pellegrini, V., Beltram, F., and Giacca, M. (2003) Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278, 34141–34149.
21. Console, S., Marty, C., Garcia-Echeverria, C., Schwendener, R., and Ballmer-Hofer, K. (2003) Antennapedia and HIV transactivator of transcription (TAT) “protein transduction domains” promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278, 35109–35114.
22. Richard, J.P., Melikov, K., Brooks, H., Prevot, P., Lebleu, B., and Chernomordik, L.V. (2005) Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparin sulfate receptors. J. Biol. Chem. 280, 15300–15306.
23. Mai, J.C., Shen, H., Watkins, S.C., Cheng, T., and Robbins, P.D. (2002) Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277, 30208–30218.
24. Tyagi, M., Rusnati, M., Presta, M., and Giacca, M. (2001) Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276, 3254–3261.
25. Sandgren, S., Cheng, F., and Belting, M. (2002) Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide: role for cell-surface proteoglycans. J. Biol. Chem. 277, 38877–38883.
26. Fischer, R., Kohler, K., Fotin-Mleczek, M., and Brock, R. (2004) A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. 279, 12625–12635.
27. Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C.,and Bogousslavsky, J. (2004) D-JNKI1, A cell-penetrating c-jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 35, 1738–1743.
28. Miao, F. J.-P., Mohammad, H.K., Velazquez, K.T., Harrison, S.D., and Sweitzer, S.M. (2008) KAI-1678, a novel inhibitor of protein kinase C epsilon, attenuates hyperalgesia and allodynia in three neuropathic pain models in rodents. Soc. Neurosci. (Abs.) 774.10.
29. Velazquez, K.T., Miao, F.J.P., Mohammad, H.K., Ogden, C.J., Harrison, S.D., and Sweitzer, S.M. (2008) KAI-1678, a novel inhibitor of protein kinase C epsilon, attenuates mechanical hyperalgesia in rodent models of acute nociceptive, inflammatory and post-surgical pain. Soc. Neurosci. (Abs.) 468.16.
30. Inagaki, K., Chen, L., Ikeno, F., Lee, F.H., Imahashi, K., Bouley, D.M., Rezaee, M., Yock, P.G., Murphy, E., Mochly-Rosen, D. (2003) Inhibition of d-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 108, 2304–2307.
31. Sho, E., Dong, J., Jin, Z., Begley, R., Chen, L., Harrison, S.D., and Mendel, D.B. (2008) Protein kinase C-d inhibitor protects against ischemic stroke by inhibiting cellular injury and inflammation and promoting astrocyte proliferation. Int. Stroke Conf. Abstr. 39, P422, 671–672.
32. Direct inhibition of d-protein kinase C enzyme to limit total infarct size in acute myocardial infarction (DELTA MI) investigators. (2008) Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117, 886–896.
33. Liu, X. J., Gingrich, J.R., Vargas-Caballero, M., Dong, Y.N., Sengar, A., Beggs, S., Wang, S.-H., Ding, H.K., Frankland, P.W., and Salter, M.W. (2008) Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nat. Med. 14, 1325–1332.
34. Sweitzer, S.M., Mohammad, H.K., Velasquez, K.T., and Harrison, S.D. (2007) Inhibition of protein kinase C epsilon translocation reduces allodynia and hyperalgesia in a rodent model of neuropathic pain. Soc. Neurosci. (Abs.) 185.2.
35. Velazquez, K.T., Mohammad, H.K., Harrison, S.D., and Sweitzer, S.M. (2007) A small peptide inhibitor of gPKC translocation attenuates allodynia and hyperalgesia in a rodent model of neuropathic pain. Soc. Neurosci. (Abs.) 185.4.
36. Rothbard, J.B., Garlington, S., Lin, Q., Kirschberg, T., Kreider, E., McGrane, P.L., Wender, P.A., and Khavari, P.A. (2000) Conjugation of arginine oligomers to cyclosporine A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6, 1253–1257.
37. Begley, R., Liron, T., Baryza, J., and Mochly-Rosen, D. (2004) Biodistribution of intracel-lularly-acting peptides conjugated reversibly to Tat. Biochem. Biophys. Res. Commun. 318, 949–954.
38. Toro, A., and Grunebaum, E. (2006) TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J. Clin. Invest. 116, 2717–2726.
39. Covic, L., Gresser, A.L., Talavera, J., Swift, S., and Kuliopulos, A. (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. U S.A. 99, 643–648.
40. Chen, L., Hahn, H., Wu, G., Chen, C.-H., Liron, T., Schechtman, D., Cavallaro, G., Banci, L., Guo, Y., Bolli, R., Dorn II, G.W., and Mochly-Rosen, D. (2001) Opposing cardioprotective actions and parallel hypertro-phic effects of dPKC and ePKC. Proc. Natl. Acad. Sci. U S.A. 98, 11114–11119.
41. Asoh, S., Ohsawa, I., Mori, T., Katsura, K., Hiraide, T., Katayama, Y., Kimura, M., Ozaki, D., Yamagata, K., and Ohta, S. (2002) Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. U.S.A. 99, 17107–17112.
42. Cao, G., Pei, W., Ge, H., Liang, Q., Luo, Y., Sharp, F.R., Lu, A., Ran, R., Graham, S.H., and Chen, J. (2002) In vivo delivery of a Bcl-xL fusion protein containing TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22, 5423–5431.
43. Bright, R., Raval, A.P., Dembner, J.M., Perez-Pinzon, M.A., Steinberg, G.K., Yenari, M.A., and Mochly-Rosen, D. (2004) Protein kinase C d mediates cerebral reperfusion injury in vivo. J. Neurosci. 24, 6880–6888.
44. Dietz, G.P.H., and Bohr, M. (2004) Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27(2), 85–131.
45. Foerg, C., and Merkle, HP. (2008) On the biomedical promise of cell penetrating peptides: limits versus prospects. J. Pharm. Sci. 97, 144–162
46. Mochly-Rosen, D. (1995) Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science 268, 247–251.
47. Mochly-Rosen, D., and Gordon, A.S. (1998) Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J. 12, 35–42.
48. L . J. Biol. Chem. 275, 37240–37245.
49. Inagaki, K., Hahn, H.S., Dorn II, G.W., and Mochly-Rosen, D. (2003) Additive protection of the ischemic heart ex vivo by combined treatment with d-protein kinase C inhibitor and e-protein kinase C activator. Circulation 108, 869–875.
50. Sivaraman, V., Hausenloy, D.J., Kolvekar, S., Hayward, M., Lawrence, D., Yap, J., Di Salvo, C., and Yellon, D.M. (2009) The divergent roles of protein kinase C epsilon and delta in simulated ischaemia-reperfusion injury in human myocardium. J. Mol Cell. Cardiol. 46, 758–764.
51. Sho, E., Dong, J., Jin, Z., Lee, Y.S., Harrison, S., and Mendel, D. (2008) Protein kinase C-d inhibitor protects against acute myocardial infarction by intravenous administration in different periods of cardiac ischemia-reperfusion. J. Am. Coll. Cardiol. Suppl. A 51(10), 1003–1086,
52. Bian, J., Popovic, Z.B., Benejam, C., Kiedrowski, M., Rodriguez, L.L., and Penn, M.S. (2007) Effect of cell-based intracellular delivery of transcription factor GATA4 on ischemic cardiomyopathy. Circ. Res. 100, 1626–1633.
53. Basbaum, A.I., and Julius, D. (2006) Toward better pain control. Sci. Am. 294(6), 61–67.
54. Woolf, C.J., and Mannion, R.J. (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353, 1959–1964.
55. Sweitzer, S. M., Wong, S.M.E., Peters, M.C., Mochly-Rosen, D., Yeomans, D.C., and Kendig, J.J. (2004) Protein kinase C e and g: involvement in formalin-induced nociception in neonatal rats. J. Pharmacol. Exp. Ther. 309, 616–625.
56. Shumilla, J.A., Liron, T., Mochly-Rosen, D., Kendig, J.J., and Sweitzer, S. M. (2005) Ethanol withdrawal-associated allodynia and hyperalgesia: age-dependent regulation by protein kinase Ce and g isozymes. J. Pain 6, 535–549.
57. Smith, F.L., Gabra, B.H., Smith, P.A., Redwood, M.C., and Dewey, W.L. (2007) Determination of the role of conventional, novel and atypical PKC isoforms in the expression of morphine tolerance in mice. Pain 127, 129–139.
58. Sweitzer, S.M., Wong, S.M.E., Tjolsen, A., Allen, C.P., Mochly-Rosen, D., and Kendig, J.J. (2004) Exaggerated nociceptive responses on morphine withdrawal: roles of protein kinase C e and g. Pain 110, 281–289.
59. Michiue, H., Tomizawa, K., Matsushita, M., Tamiya, T., Lu, Y.F., Ichikawa, T., Date, I., and Matsui, H. (2005) Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett. 579, 3965–3969.
60. Snyder, E.L., Meade, B.R., Saenz, C.C., and Dowdy, S.F. (2004) Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. 2, 186–193.
61. Yoshiji, H., Kuriyama, S., Ways, D.K., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Tsujinoue, H., Nakatani, T., Shibuya, M., and Fukui, H. (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59, 4413–4418.
62. Kim, J., Choi, Y.-L., Vallentin, A., Hunrichs, B.S., Hellerstein, M.K., Peehl, D.M., and Mochly-Rosen, D. (2008) Centrosomal PKCbII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 68(16), 6831–6839.
63. Meyer-Losic, F., Quinonero, J., Dubois, V., Alluis, B., Dechambre, M., Michel, M., Callier, F., Fernandez, A.-M., Trouet, A., and Kearsey, J. (2006) Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell). J. Med. Chem. 49(23), 6908–6916.
64. Meyer-Losic, F., Nicolazzi, C., Quinonero, J., Ribes, F., Michel, M., Dubois, V., de Coupade, C., Boukaissi, M., Chene, A.-S., Tranchant, I., Arranz, V., Zoubaa, I., Fruchart, J.-S., Ravel, D., and Kearsey, J. (2008) DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin. Cancer Res. 14(7), 2145–2153.
65. Roe, M.T., Ohman, E.M., Maas, A.C.P., Christenson, R.H., Mahaffey, K.W., Granger, C.B., Harrington, R.A., Califf, R.M., and Krucoff, M.W. (2001) Shifting the open artery hypothesis downstream: the quest for optimal reperfusion. J. Am. Coll. Cardiol. 37, 9–18.
66. Wang, J., Van De Water, T.R., Bonny, C., de Ribaupierre, F., Puel, J.L., and Zine, A. (2003) A peptide inhibitor of c-jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J. Neurosci. 23, 8596–8607.
67. Glogau, R.G. (2007) Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded vehicle-contolled study. Dermatol. Surg. 33, S76–S80.
68. Lopes, L.B., Furnish, E.J., Komalavilas, P., Flynn, C.R., Ashby, P., Hansen, A., Ly, D.P., Yang, G.P., Longaker, M.T., Panitch, A., and Brophy, C.M. (2009) Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-b1-induced CTGF expression in keloid fibroblasts. J. Invest. Dermatol. 129, 590–598.